Search
Washington Paid Clinical Trials
A listing of 1772 clinical trials in Washington actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 1772
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Washington is currently home to 1772 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: North Sound Dermatology, Mill Creek, Washington
Conditions: Atopic Dermatitis
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Investigative Site US308, Spokane, Washington
Conditions: Hidradenitis Suppurativa (HS)
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Spokane Valley, Washington
Conditions: Metastatic Castration-Sensitive Prostate Cancer
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Premier Clinical Research, Spokane, Washington
Conditions: NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Dermatology Specialists of Spokane, Spokane, Washington
Conditions: NonSegmental Vitiligo
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Kadlec Clinic Hematology and Oncology ( Site 0103), Kennewick, Washington
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Tacoma, Washington
Conditions: Metastatic Non-small Cell Lung Cancer
A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Recruiting
FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Everett, Washington
Conditions: ADHD
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Recruiting
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2024
Locations: Bellingham Asthma, Allergy Immunology Clinic, Bellingham, Washington
Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
04/25/2024
Locations: Spokane Eye Clinic, Spokane, Washington
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/25/2024
Locations: Premier Clinical Research, Spokane, Washington
Conditions: Prurigo